Dr. Susan Learned, M.D., Pharm.D., Ph.D., is the Senior Vice President of Global Medicines Development at Indivior, a global pharmaceutical company based in Richmond, VA focused on developing medicines for patients with addictions and comorbid disorders.  Susan’s 20+ years of expertise in the pharmaceutical industry spans all phases of drug discovery and development. She has managed large, global multidisciplinary drug discovery and development organizations, leading the design of innovative clinical trials to make efficient business decisions, implementing biomarkers and translational medicine tools across therapeutic areas, contributing to business development strategies and operations, developing high performing teams, and providing mentorship for globally diverse team members in leadership roles.

Prior to joining Indivior in 2015, Susan was the VP, Medicines Development Lead and Franchise Lead for Psoriasis and Atopic Dermatitis at Stiefel, GSK’s Dermatology company.   In that role, she led medicines development, including strategic and operational teams accountable for all areas of R&D and Commercial strategy for all assets from preclinical development through life cycle management. Susan was previously VP of Discovery Medicine for GSK in China where she set up the early development neuroscience organization for GSK in Shanghai by leading all clinical development activities for the global neurology pipeline including translational medicine, experimental medicine, data management and discovery biometrics, clinical operations, epidemiology and clinical pharmacokinetics, modeling and simulation. Previous roles included being the Head of Neurosciences Discovery Scientific Licensing for GSK’S Worldwide Business Development organization, Head of GSK’S Neurosciences Discovery Medicine, and Head of Clinical Pharmacology and Discovery Medicine for GSK’S Psychiatry Center for Excellence in Drug Discovery, where she developed and implemented strategic clinical development plans for all compounds within GSK’s neurosciences pipeline. Susan’s key contributions have included several worldwide regulatory approvals, including WELLBUTRIN for major depressive disorder, ZYBAN for smoking cessation, NAVELBINE for non-small-cell lung cancer, NAVELBINE for breast cancer, REQUIP for restless leg syndrome, LAMICTAL for the maintenance treatment of bipolar I disorder, POTIGA for partial onset seizures, SORILUX for body psoriasis, SORILUX for scalp psoriasis, and SUBLOCADE for opioid use disorder.

Susan obtained her BS Pharmacy and MD degrees at Union University’s Albany College of Pharmacy and Albany Medical College, Albany, NY, her internal medicine residency training at Erie County Medical Center, Buffalo, NY, and her PharmD and PhD (neurobehavioral clinical pharmacology) degrees at the Medical College of Virginia / Virginia Commonwealth University.   She has served on numerous boards, including the National Institute on Drug Abuse’s Medications Development Advisory Board, Albany College of Pharmacy and Health Sciences’ Board of Trustees, the Medical College of Viriginia/ VCU’s School of Pharmacy Graduate Advisory Board and the School of Pharmacy and School of Medicine’s National Advisory Council.   She has also been a Visiting Professor in the FDA’s Neuropharm division on the use of neuroimaging in drug development and her work with the SFDA/CFDA in China has helped to influence change in that Agency so as to encourage adoption of Western regulatory guidances.